ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2013
Peripheral endocannabinoid system dysregulation in first-episode psychosis.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning.European psychiatry : the journal of the Association of European Psychiatrists · 2020Pooled it
- Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis.JAMA psychiatry · 2019Pooled it
- Towards Mechanism-Informed Treatments for Mental Health.Journal of neurochemistry · 2026Review
- Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication.European archives of psychiatry and clinical neuroscience · 2025Article
- Self-disturbance in first-episode psychosis: Theoretical framework and potential cannabis interactions - a systematic review.Frontiers in psychiatry · 2025Review
- Differences in total and differential white blood cell counts and in inflammatory parameters between psychiatric inpatients with and without recent consumption of cannabinoids, opioids, or cocaine: A retrospective single-center study.Brain, behavior, & immunity - health · 2024Article
- An exploratory study of metabolomics in endogenous and cannabis-use-associated psychotic-like experiences in adolescence.Translational psychiatry · 2024Article
- Selective alterations of endocannabinoid system genes expression in obsessive compulsive disorder.Translational psychiatry · 2024Article
- Article
- Cannabis Pharmacogenomics: A Path to Personalized Medicine.Current issues in molecular biology · 2023Review
- Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.International journal of molecular sciences · 2022Review
- New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders.International journal of molecular sciences · 2022Review
- A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders.The international journal of neuropsychopharmacology · 2021Article
- Endocannabinoid system in psychotic and mood disorders, a review of human studies.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Cannabis Use Induces Distinctive Proteomic Alterations in Olfactory Neuroepithelial Cells of Schizophrenia Patients.Journal of personalized medicine · 2021Article
- The Endocannabinoid System as Modulator of Exercise Benefits in Mental Health.Current neuropharmacology · 2021Review
- Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.Biomolecules · 2020Review
- Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis.Biological psychiatry · 2020Article
- Cannabinoids and their therapeutic applications in mental disorders .Dialogues in clinical neuroscience · 2020Review
- Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis.NPJ schizophrenia · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several hypotheses involving alterations of the immune system have been proposed among etiological explanations for psychotic disorders. The endocannabinoid system (ECS) has a homeostatic role as an endogenous neuroprotective and anti-inflammatory system. Alterations of this system have been associated with psychosis. Cannabis use is a robust risk factor for these disorders that could alter the ECS signalling. In this study, 95 patients with a first episode of psychosis (FEP) and 90 healthy controls were recruited. Protein expression of cannabinoid receptor 2 (CB2), the protein levels of the main endocannabinoid synthesizing enzymes N-acyl phosphatidylethanolamine phospholipase (NAPE) and diacylglycerol lipase (DAGL), and of degradation enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) were determined by western blot analysis in peripheral blood mononuclear cells (PBMCs). Patients with a FEP showed a decreased expression of CB2 and of both endocannabinoids synthesizing enzymes (NAPE and DAGL) in comparison to healthy controls. After controlling for age, gender, body mass index, and cannabis use, NAPE and DAGL expression remained significantly decreased, whereas FAAH and MAGL expression were increased. On the other hand, FEP subjects with history of severe cannabis use showed a larger ECS dysregulation compared with healthy controls. These results indicate an ECS dysregulation in PBMC of FEP patients. The alteration of the ECS presented at the initial phases of psychosis could be contributing to the pathophysiology of the disease and constitutes a possible biomarker of psychotic disorders and an interesting pharmacological target to take into account for therapeutic purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.